Edition:
India

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

88.04CHF
12 Dec 2018
Change (% chg)

-- (--)
Prev Close
CHF88.04
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
4,538,461
52-wk High
CHF92.80
52-wk Low
CHF71.84

Select another date:
Photo

J&J says its psoriasis drug superior to Novartis treatment in study

Johnson & Johnson said its drug, Tremfya, was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderate-to-severe plaque psoriasis in a late-stage study.

UPDATE 2-J&J says its psoriasis drug superior to Novartis treatment in study

Dec 12 Johnson & Johnson said its drug, Tremfya, was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderate-to-severe plaque psoriasis in a late-stage study.

J&J says its psoriasis drug superior to Novartis' in study

Dec 12 Johnson & Johnson said on Wednesday its drug Tremfya was more effective than a rival medicine from Novartis AG, and met the main goal of a late-stage study in adults with moderate to severe plaque psoriasis.

Novartis to launch Adamis' EpiPen rival in U.S. next year

Dec 6 Novartis AG said its U.S. unit Sandoz Inc will launch Adamis Pharmaceuticals Corp's emergency allergy shots next year in the United States, at a price that is about 16 percent below that of similar rival products.

Novartis's new treatment for hives outperforms Xolair in trials

ZURICH Novartis said on Tuesday it was taking its experimental medicine ligelizumab to late-stage trials after the drug showed signs of outperforming existing product Xolair in treating severe urticaria, also known as hives.

Novartis's new treatment for hives outperforms Xolair in trials

ZURICH Novartis said on Tuesday it was taking its experimental medicine ligelizumab to late-stage trials after the drug showed signs of outperforming existing product Xolair in treating severe urticaria, also known as hives.

UPDATE 1-Novartis's new treatment for hives outperforms Xolair in trials

ZURICH, Dec 4 Novartis said on Tuesday it was taking its experimental medicine ligelizumab to late-stage trials after the drug showed signs of outperforming existing product Xolair in treating severe urticaria, also known as hives.

Novartis goes after Roche asthma medicine Xolair with new drug

ZURICH, Dec 4 Novartis said it is pushing ahead with a late-stage study of its experimental drug ligelizumab after announcing the medicine outperformed Roche's Xolair in a Phase II clinical trial against urticaria, also known as hives.

Novartis SMA treatment could get FDA approval in May

ZURICH Novartis's gene therapy for spinal muscular atrophy (SMA) could be approved in May 2019 after the U.S. Food and Drug Administration agreed to an accelerated review of the Swiss drugmaker's treatment.

Novartis SMA treatment could get FDA approval in May

ZURICH, Dec 3 Novartis's gene therapy for spinal muscular atrophy (SMA) could be approved in May 2019 after the U.S. Food and Drug Administration agreed to an accelerated review of the Swiss drugmaker's treatment.

Select another date: